104 related articles for article (PubMed ID: 21800006)
21. Different metabolic correlations of thrombin-activatable fibrinolysis inhibitor and plasminogen activator inhibitor-1 in non-obese type 2 diabetic patients.
Kitagawa N; Yano Y; Gabazza EC; Bruno NE; Araki R; Matsumoto K; Katsuki A; Hori Y; Nakatani K; Taguchi O; Sumida Y; Suzuki K; Adachi Y
Diabetes Res Clin Pract; 2006 Aug; 73(2):150-7. PubMed ID: 16458385
[TBL] [Abstract][Full Text] [Related]
22. Serum adiponectin concentrations predict the developments of type 2 diabetes and the metabolic syndrome in elderly Koreans.
Choi KM; Lee J; Lee KW; Seo JA; Oh JH; Kim SG; Kim NH; Choi DS; Baik SH
Clin Endocrinol (Oxf); 2004 Jul; 61(1):75-80. PubMed ID: 15212647
[TBL] [Abstract][Full Text] [Related]
23. Plasminogen activator inhibitor-1 is associated with coronary artery calcium in Type 1 diabetes.
Pratte KA; Barón AE; Ogden LG; Hassell KL; Rewers M; Hokanson JE
J Diabetes Complications; 2009; 23(6):387-93. PubMed ID: 18768333
[TBL] [Abstract][Full Text] [Related]
24. PAI-1 4G/5G insertion/deletion promoter polymorphism and microvascular complications in type 2 diabetes mellitus.
Funk M; Endler G; Exner M; Marculescu R; Endler L; Abrahamian H; Mauler H; Grimm A; Raith M; Mannhalter C; Prager R; Irsigler K; Wagner OF
Wien Klin Wochenschr; 2005 Oct; 117(19-20):707-10. PubMed ID: 16416371
[TBL] [Abstract][Full Text] [Related]
25. [The influences of genetic and environmental factors on plasma plasminogen activator inhibitor-1 levels in patients with essential hypertension].
Song Y; Xu W; Chen Y; Che L; Wang Q; Zhou X; Wu J
Zhonghua Yi Xue Yi Chuan Xue Za Zhi; 1999 Dec; 16(6):374-6. PubMed ID: 10581347
[TBL] [Abstract][Full Text] [Related]
26. Enhancement of fibrinolysis in poorly controlled, hospitalized type 2 diabetic patients by short-term metabolic control: association with a decrease in plasminogen activator inhibitor 1.
Aso Y; Okumura KI; Yoshida N; Tayama K; Takemura Y; Inukai T
Exp Clin Endocrinol Diabetes; 2004 Apr; 112(4):175-80. PubMed ID: 15127320
[TBL] [Abstract][Full Text] [Related]
27. Association of plasma markers of cholesterol homeostasis with metabolic syndrome components. A cross-sectional study.
Cofán M; Escurriol V; García-Otín AL; Moreno-Iribas C; Larrañaga N; Sánchez MJ; Tormo MJ; Redondo ML; González CA; Corella D; Pocoví M; Civeira F; Ros E
Nutr Metab Cardiovasc Dis; 2011 Sep; 21(9):651-7. PubMed ID: 20554170
[TBL] [Abstract][Full Text] [Related]
28. Serum complement C3: a determinant of cardiometabolic risk, additive to the metabolic syndrome, in middle-aged population.
Onat A; Hergenç G; Can G; Kaya Z; Yüksel H
Metabolism; 2010 May; 59(5):628-34. PubMed ID: 19913840
[TBL] [Abstract][Full Text] [Related]
29. Factors accounting for high ferritin levels in obesity.
Lecube A; Hernández C; Pelegrí D; Simó R
Int J Obes (Lond); 2008 Nov; 32(11):1665-9. PubMed ID: 18779821
[TBL] [Abstract][Full Text] [Related]
30. Effect of 4G/5G PAI-1 polymorphism on the response of PAI-1 activity to vitamin E supplementation in Type 2 diabetic patients.
Testa R; Bonfigli AR; Sirolla C; Boemi M; Manfrini S; Mari D; Testa I; Sacchi E; Franceschi C
Diabetes Nutr Metab; 2004 Aug; 17(4):217-21. PubMed ID: 15575342
[TBL] [Abstract][Full Text] [Related]
31. The -675 4G/5G polymorphism at the Plasminogen Activator Inhibitor 1 (PAI-1) gene modulates plasma Plasminogen Activator Inhibitor 1 concentrations in response to dietary fat consumption.
Pérez-Martínez P; Adarraga-Cansino MD; Fernández de la Puebla RA; Blanco-Molina A; Delgado-Lista J; Marín C; Ordovás JM; López-Miranda J; Pérez-Jiménez F
Br J Nutr; 2008 Apr; 99(4):699-702. PubMed ID: 17903340
[TBL] [Abstract][Full Text] [Related]
32. Common quantitative trait locus downstream of RETN gene identified by genome-wide association study is associated with risk of type 2 diabetes mellitus in Han Chinese: a Mendelian randomization effect.
Chung CM; Lin TH; Chen JW; Leu HB; Yin WH; Ho HY; Sheu SH; Tsai WC; Chen JH; Lin SJ; Pan WH
Diabetes Metab Res Rev; 2014 Mar; 30(3):232-40. PubMed ID: 24123702
[TBL] [Abstract][Full Text] [Related]
33. Number of metabolic syndrome risk parameters associated with TAFIa/ai antigen levels.
Gunes F; Akbal E; Asik M; Sen H; Binnetoglu E; Kizilgun M; Ozbek M
Blood Coagul Fibrinolysis; 2013 Dec; 24(8):844-7. PubMed ID: 23945058
[TBL] [Abstract][Full Text] [Related]
34. Association of plasminogen activator inhibitor-1 and tissue plasminogen activator with type 2 diabetes and metabolic syndrome in Malaysian subjects.
Al-Hamodi Z; Ismail IS; Saif-Ali R; Ahmed KA; Muniandy S
Cardiovasc Diabetol; 2011 Mar; 10():23. PubMed ID: 21414238
[TBL] [Abstract][Full Text] [Related]
35. Fibroblast growth factor-19 levels in type 2 diabetic patients with metabolic syndrome.
Barutcuoglu B; Basol G; Cakir Y; Cetinkalp S; Parildar Z; Kabaroglu C; Ozmen D; Mutaf I; Bayindir O
Ann Clin Lab Sci; 2011; 41(4):390-6. PubMed ID: 22166511
[TBL] [Abstract][Full Text] [Related]
36. Plasminogen activator inhibitor-1 levels in patients with primary varicose vein.
Erguzel N; Yetkin E; Erdem G; Erdil N; Yetkin G; Heper G; Celik T; Senen K
Int Angiol; 2012 Apr; 31(2):176-80. PubMed ID: 22466984
[TBL] [Abstract][Full Text] [Related]
37. Effect of plasminogen activator inhibitor-1 and tissue plasminogen activator polymorphisms on susceptibility to type 2 diabetes in Malaysian subjects.
Al-Hamodi Z; Saif-Ali R; Ismail IS; Ahmed KA; Muniandy S
J Biomed Biotechnol; 2012; 2012():234937. PubMed ID: 22577291
[TBL] [Abstract][Full Text] [Related]
38. Metabolic changes in type 2 diabetes are reflected in peripheral blood cells, revealing aberrant cytotoxicity, a viral signature, and hypoxia inducible factor activity.
van der Pouw Kraan TC; Chen WJ; Bunck MC; van Raalte DH; van der Zijl NJ; van Genugten RE; van Bloemendaal L; Baggen JM; Serné EH; Diamant M; Horrevoets AJ
BMC Med Genomics; 2015 May; 8():20. PubMed ID: 25956355
[TBL] [Abstract][Full Text] [Related]
39. Plasminogen Activator Inhibitor Type-1 Tag Single-Nucleotide Polymorphisms in Patients with Diabetes Mellitus Type 2 and Diabetic Retinopathy.
Siokas V; Dardiotis E; Sokolakis T; Kotoula M; Tachmitzi SV; Chatzoulis DZ; Almpanidou P; Stefanidis I; Hadjigeorgiou GM; Tsironi EE
Curr Eye Res; 2017 Jul; 42(7):1048-1053. PubMed ID: 28632032
[TBL] [Abstract][Full Text] [Related]
40. Plasma Levels of Plasminogen Activator Inhibitor Type 1 and Vitronectin in Children With Cancer.
Tugcu D; Devecioglu O; Unuvar A; Ekmekci H; Ekmekci OB; Anak S; Ozturk G; Akcay A; Aydogan G
Clin Appl Thromb Hemost; 2016 Jan; 22(1):28-33. PubMed ID: 24770328
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
